tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: T2 Biosystems (TTOO), Poseida Therapeutics (PSTX) and COMPASS Pathways (CMPS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on T2 Biosystems (TTOOResearch Report), Poseida Therapeutics (PSTXResearch Report) and COMPASS Pathways (CMPSResearch Report).

T2 Biosystems (TTOO)

BTIG analyst Mark Massaro reiterated a Hold rating on T2 Biosystems on October 12. The company’s shares closed last Thursday at $2.55.

According to TipRanks.com, Massaro ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.9% and a 39.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Adaptive Biotechnologies.

The the analyst consensus on T2 Biosystems is currently a Hold rating.

See the top stocks recommended by analysts >>

Poseida Therapeutics (PSTX)

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Poseida Therapeutics, with a price target of $20.00. The company’s shares closed last Thursday at $4.36.

According to TipRanks.com, Zelin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.0% and a 31.0% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Precision BioSciences, CASI Pharmaceuticals, and Immunocore Holdings.

Currently, the analyst consensus on Poseida Therapeutics is a Moderate Buy with an average price target of $15.50.

COMPASS Pathways (CMPS)

BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways yesterday and set a price target of $47.00. The company’s shares closed last Thursday at $10.11, close to its 52-week low of $6.54.

According to TipRanks.com, Hazlett is a 2-star analyst with an average return of -1.0% and a 37.2% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Paratek Pharmaceuticals, and Axsome Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for COMPASS Pathways with a $55.60 average price target, which is a 432.1% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TTOO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles